Assessment of safety and efficacy of biphasic human insulin IU 100 to EX1000 on glycaemic control in subjects with type 2 diabetes

Trial Profile

Assessment of safety and efficacy of biphasic human insulin IU 100 to EX1000 on glycaemic control in subjects with type 2 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs EX 1000; Insulin suspension isophane/insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Sep 2012 Planned number of patients changed from 400 to 480.
    • 25 Aug 2011 New source identified and integrated (Clinical Trial Registry - India, CTRI2008-091-000035).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top